76,999,515 Equity Shares of Glenmark Life Sciences Limited are subject to a Lock-Up Agreement Ending on 2-AUG-2022. These Equity Shares will be under lockup for 368 days starting from 30-JUL-2021 to 2-AUG-2022.

Details:
An aggregate of 20% of the post-issue shareholding of the company held by the promoters will be locked-in for a period of three years from the date of allotment in the issue.

Promoters' shareholding in excess of 20% of the fully diluted post-Issue Equity Share capital shall be locked in for a period of one year from the date of Allotment.